文献速递糖尿病

鱼油、血浆n-3多不饱和脂肪酸与2型糖尿病患者大血管及微血管并发症风险

Fish Oil, Plasma n-3 PUFAs, and Risk of Macro- and Microvascular Complications Among Individuals With Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

基于英国生物银行20338例2型糖尿病患者,随访13.2年,发现鱼油补充剂使用与复合大血管并发症(HR 0.90)及复合微血管并发症(HR 0.89)风险降低相关;血浆n-3多不饱和脂肪酸(尤其DHA)较高水平也与上述风险降低相关,且部分由血脂谱和炎症标志物介导。

要点

  • 鱼油补充剂使用与复合大血管并发症HR 0.90(95%CI 0.85-0.97)及复合微血管并发症HR 0.89(95%CI 0.83-0.95)相关。
  • 血浆DHA最高四分位组较最低四分位组复合大血管并发症HR 0.68(95%CI 0.57-0.81)。
  • 血脂谱和炎症标志物 collectively 解释DHA与复合大血管并发症关联的54.4%、与冠心病关联的63.1%。

核心结论

  • 习惯性使用鱼油补充剂和较高血浆n-3多不饱和脂肪酸水平(尤其DHA)与2型糖尿病患者大血管及微血管并发症风险降低相关,且有利关联部分通过改善血脂谱和炎症标志物介导。

研究设计与样本

  • 研究纳入英国生物银行20338例2型糖尿病患者,通过医院住院记录识别糖尿病并发症。

主要发现

  • 随访13.2年期间,5396人发生大血管并发症,4868人发生微血管并发症。
  • 多变量调整后,使用鱼油的患者复合大血管并发症HR 0.90(95%CI 0.85-0.97),冠心病HR 0.91(95%CI 0.84-0.98),外周动脉疾病HR 0.72(95%CI 0.61-0.83)。
  • 使用鱼油的患者复合微血管并发症HR 0.89(95%CI 0.83-0.95),糖尿病肾病HR 0.87(95%CI 0.79-0.95),糖尿病视网膜病变HR 0.88(95%CI 0.80-0.97)。
  • 血浆DHA最高四分位组与最低四分位组比较,复合大血管并发症HR 0.68(95%CI 0.57-0.81),冠心病HR 0.63(95%CI 0.51-0.77),糖尿病神经病变HR 0.59(95%CI 0.38-0.91)。
  • 血脂谱和炎症标志物等生物标志物 collectively 解释血浆DHA与复合大血管并发症关联的54.4%、与冠心病关联的63.1%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate associations of fish oil supplementation and plasma omega 3 polyunsaturated fatty acids (n-3 PUFAs) with risks of macrovascular and microvascular complications among people with type 2 diabetes and to further explore the potential mediating role of metabolism-related biomarkers. RESEARCH DESIGN AND METHODS: This study included 20 338 participants with type 2 diabetes from the UK Biobank. Diabetic complications were identified through hospital inpatient records. RESULTS: During 13.2 years of follow-up, 5396 people developed macrovascular complications, and 4868 people developed microvascular complications. After multivariable adjustment, hazard ratios (HRs) and 95% confidence intervals (CIs) for patients with fish oil were 0.90 (0.85, 0.97) for composite macrovascular complications, 0.91 (0.84, 0.98) for coronary heart disease (CHD), 0.72 (0.61, 0.83) for peripheral artery disease and 0.89 (0.83, 0.95) for composite microvascular complications, 0.87 (0.79, 0.95) for diabetic kidney disease, and 0.88 (0.80, 0.97) for diabetic retinopathy. In addition, higher n-3 PUFA levels, especially docosahexaenoic acid (DHA), were associated with lower risks of macrovascular and microvascular complications. Comparing extreme quartiles of plasma DHA, the HRs (95% CIs) were 0.68 (0.57, 0.81) for composite macrovascular complications, 0.63 (0.51, 0.77) for CHD, and 0.59 (0.38, 0.91) for diabetic neuropathy. Moreover, biomarkers including lipid profile and inflammatory markers collectively explained 54.4% and 63.1% of associations of plasma DHA with risks of composite macrovascular complications and CHD. CONCLUSION: Habitual use of fish oil supplementation and higher plasma n-3 PUFA levels, especially DHA, were associated with lower risks of macrovascular and microvascular complications among individuals with type 2 diabetes, and the favorable associations were partially mediated through improving biomarkers of lipid profile and inflammation.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tian S, Guo T, Qian F, et al. Fish Oil, Plasma n-3 PUFAs, and Risk of Macro- and Microvascular Complications Among Individuals With Type 2 Diabetes. J Clin Endocrinol Metab. 2025. PMID: 38994586. doi:10.1210/clinem/dgae482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。